Getagraph.com logo
S&P 500
(0.94%) 5 065.77 points
Dow Jones
(0.90%) 38 244 points
Nasdaq
(1.50%) 15 840 points
Oil
(0.22%) $79.17
Gas
(6.11%) $2.05
Gold
(0.21%) $2 315.80
Silver
(0.64%) $26.92
Platinum
(1.09%) $965.35
USD/EUR
(-0.09%) $0.932
USD/NOK
(-0.38%) $10.99
USD/GBP
(-0.10%) $0.798
USD/RUB
(-1.38%) $91.97

Realaus laiko atnaujinimai FibroGen Inc [FGEN]

Birža: NASDAQ Sektorius: Healthcare Pramonė: Biotechnology
Upcoming Earnings Alert

4 days till quarter result
(amc 2024-05-06)

Expected move: +/- 6.41%

BUY
62.50%
return 6.02%
SELL
44.44%
return -3.27%
Atnaujinta2 geg. 2024 @ 21:47
25% discount on Stockinvest.us - Use code: Podcast

2.56% $ 1.200

PIRKIMAS 112192 min ago

@ $2.26

Išleistas: 14 vas. 2024 @ 22:55

Grąža: -46.90%

Ankstesnis signalas: vas. 14 - 22:23

Ankstesnis signalas: Pardavimas

Grąža: -2.38 %

Live Chart Being Loaded With Signals

Commentary (2 geg. 2024 @ 21:47):

FibroGen, Inc., a biopharmaceutical company, discovers, develops, and commercializes therapeutics to treat serious unmet medical needs. The company is developing Roxadustat, an oral small molecule inhibitor of hypoxia inducible factor prolyl hydroxylases, which has completed Phase III clinical development for the treatment of anemia in chronic kidney disease in the United States, Europe, China, and Japan; and in Phase II/III development in China for anemia associated with myelodysplastic syndromes...

Stats
Šios dienos apimtis 447 064
Vidutinė apimtis 1.99M
Rinkos kapitalizacija 119.37M
EPS $0 ( 2024-02-26 )
Kita pelno data ( $-0.310 ) 2024-05-06
Last Dividend $0 ( N/A )
Next Dividend $0 ( N/A )
P/E -0.410
ATR14 $0.00400 (0.33%)
Insider Trading
Date Person Action Amount type
2024-04-22 Adib Deyaa Sell 0 Common Stock
2024-04-22 Adib Deyaa Sell 300 000 Stock Option (Right to Buy)
2024-03-22 Wettig Thane Sell 782 Common Stock
2024-03-07 Wettig Thane Buy 50 000 Common Stock
2024-03-06 Graham Juan Buy 781 Common Stock
INSIDER POWER
64.61
Last 100 transactions
Buy: 2 904 321 | Sell: 578 976

Tūris Koreliacija

Ilgas: 0.06 (neutral)
Trumpas: 0.00 (neutral)
Signal:(46.587) Neutral

FibroGen Inc Koreliacija

10 Labiausiai teigiamai susiję koreliacijos
FCBP0.909
SMMT0.904
CCOI0.901
FGM0.897
YQ0.893
FEP0.89
EUFN0.889
BNIXU0.887
CID0.887
NIU0.886
10 Labiausiai neigiamai susiję koreliacijos
PCRX-0.904
SLDP-0.891
MARK-0.887
PFBI-0.887
WKSP-0.885
RCMT-0.884
NTLA-0.882
ONDS-0.875
LARK-0.875
RDHL-0.869

Ar žinojote?

Koreliacija yra statistinis rodiklis, aprašantis ryšį tarp dviejų kintamųjų. Jis svyruoja nuo -1 iki 1, kur -1 reiškia tobulo neigiamo ryšio koreliaciją (padidėjus vienam kintamajam, sumažėja kitas), 1 reiškia tobulo teigiamo ryšio koreliaciją (padidėjus vienam kintamajam, padidėja ir kitas), o 0 reiškia jokios koreliacijos (tarp kintamųjų nėra jokio ryšio).

Koreliacija gali būti naudojama analizuojant bet kurių dviejų kintamųjų ryšį, ne tik akcijų. Jis dažnai naudojamas finansų, ekonomikos, psichologijos ir kitose srityse.

FibroGen Inc Koreliacija - Valiuta/Žaliavos

The country flag 0.19
( neutral )
The country flag 0.34
( neutral )
The country flag 0.00
( neutral )
The country flag 0.00
( neutral )
The country flag 0.00
( neutral )
The country flag -0.36
( neutral )

FibroGen Inc Finansinės ataskaitos

Annual 2023
Pajamos: $147.75M
Bruto pelnas: $128.90M (87.24 %)
EPS: $-2.92
FY 2023
Pajamos: $147.75M
Bruto pelnas: $128.90M (87.24 %)
EPS: $-2.92
FY 2022
Pajamos: $140.73M
Bruto pelnas: $120.45M (85.59 %)
EPS: $-3.15
FY 2021
Pajamos: $235.31M
Bruto pelnas: $222.44M (94.53 %)
EPS: $-3.13

Financial Reports:

No articles found.

FibroGen Inc

FibroGen, Inc., a biopharmaceutical company, discovers, develops, and commercializes therapeutics to treat serious unmet medical needs. The company is developing Roxadustat, an oral small molecule inhibitor of hypoxia inducible factor prolyl hydroxylases, which has completed Phase III clinical development for the treatment of anemia in chronic kidney disease in the United States, Europe, China, and Japan; and in Phase II/III development in China for anemia associated with myelodysplastic syndromes. It is also developing Pamrevlumab, a human monoclonal antibody that inhibits the activity of connective tissue growth factor that is in Phase III clinical development for the treatment of idiopathic pulmonary fibrosis, pancreatic cancer, liver fibrosis, and diabetic kidney disease, as well as Phase III trial for the treatment of Duchenne muscular dystrophy. The company has collaboration agreements with Astellas Pharma Inc. and AstraZeneca AB. FibroGen, Inc. was incorporated in 1993 and is headquartered in San Francisco, California.

Apie Signalai gyvai

Šiame puslapyje pateikti tiesioginiai signalai padeda nustatyti, kada PIRKTI ar PARDUOTI NA. Signalai vėluoja 1 minutę; kaip ir su visais rinkos signalais, taip ir su šiais, visuomet yra klaidų tikimybė.

Tiesioginiai prekybos signalai nėra apibrėžti, todėl getagraph.com neprisiima atsakomybės už jokius veiksmus, kurių buvo imtasi žinant šiuos signalus, kaip aprašyta Naudojimo sąlygose. Signalai yra pagrįsti įvairiais techninės analizės rodikliais.